Furthermore, meropenem is administered less frequently than imipenem-cilastatin and may be associated with a lower frequency of gastrointestinal adverse effects. [1] Generally, carbapenems have ...
It is unknown whether ertapenem is associated with similar clinical response and microbiologic cure rates as those achieved with group 2 carbapenems (imipenem, meropenem, doripenem). Objective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback